{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:11:54Z","timestamp":1788376314233,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T00:00:00Z","timestamp":1637452800000},"content-version":"am","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.revmed.2020.06.006","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T01:50:58Z","timestamp":1595469058000},"page":"748-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dosage de la tryptase\u00a0: un guide d'utilisation pour le clinicien"],"prefix":"10.1016","volume":"41","author":[{"given":"H.","family":"Lobbes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Reynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mainbourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Lega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Durupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2020.06.006_bb0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12016-015-8487-6","article-title":"Mast cell activation syndrome","volume":"54","author":"Frieri","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.yexcr.2016.03.013","article-title":"The development of human mast cells. An historical reappraisal","volume":"342","author":"Ribatti","year":"2016","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.revmed.2020.06.006_bb0020","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri1460","article-title":"Mast-cell responses to pathogens","volume":"4","author":"Marshall","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/ijms20030481","article-title":"Mast cells and angiogenesis in human plasma cell malignancies","volume":"20","author":"Ribatti","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.revmed.2020.06.006_bb0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/cells9030701","article-title":"Local mast cell activation promotes neovascularization","volume":"9","author":"Bot","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.revmed.2020.06.006_bb0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/imr.12626","article-title":"The controversial role of mast cells in fibrosis","volume":"282","author":"Bradding","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.revmed.2020.06.006_bb0040","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nri3690","article-title":"Mast cell secretory granules: armed for battle","volume":"14","author":"Wernersson","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0045","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ni.2109","article-title":"Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils","volume":"12","author":"Galli","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1067\/mai.2002.121454","article-title":"Characterization of mast-cell tryptase-expressing peripheral blood cells as basophils","volume":"109","author":"Foster","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000337735","article-title":"Pathophysiologic role of histamine: evidence clarified by histidine decarboxylase gene knockout mice","volume":"158","author":"Ohtsu","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0060","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/j.1742-4658.2006.05211.x","article-title":"Biology of mast cell tryptase. An inflammatory mediator","volume":"273","author":"Hallgren","year":"2006","journal-title":"FEBS J"},{"key":"10.1016\/j.revmed.2020.06.006_bb0065","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.intimp.2007.07.007","article-title":"Active monomers of human \u03b2-tryptase have expanded substrate specificities","volume":"7","author":"Fukuoka","year":"2007","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0070","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2008.01.019","article-title":"Chimerism, point mutation, and truncation dramatically transformed mast cell \u03b4-tryptases during primate evolution","volume":"121","author":"Trivedi","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molimm.2014.04.001","article-title":"Human mast cell tryptase in biology and medicine","volume":"63","author":"Vitte","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0080","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/cea.12259","article-title":"Alpha-tryptase gene variation is associated with levels of circulating IgE and lung function in asthma","volume":"44","author":"Abdelmotelb","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.revmed.2020.06.006_bb0085","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.anai.2013.07.011","article-title":"Genetic factors account for most of the variation in serum tryptase\u2014a twin study","volume":"111","author":"Sverrild","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.revmed.2020.06.006_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.01.012","article-title":"Usefulness of testing for hereditary alpha tryptasemia in symptomatic patients with elevated tryptase","volume":"8","author":"Carrigan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.revmed.2020.06.006_bb0095","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaci.2011.04.011","article-title":"Heparanase affects secretory granule homeostasis of murine mast cells through degrading heparin","volume":"128","author":"Wang","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0100","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1172\/JCI118523","article-title":"A novel heparin-dependent processing pathway for human tryptase. Autocatalysis followed by activation with dipeptidyl peptidase I","volume":"97","author":"Sakai","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2020.06.006_bb0105","doi-asserted-by":"crossref","first-page":"20785","DOI":"10.1074\/jbc.R700017200","article-title":"Mast cell-restricted tryptases: structure and function in inflammation and pathogen defense","volume":"282","author":"McNeil","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.revmed.2020.06.006_bb0110","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.molimm.2010.04.020","article-title":"Serine proteases of the human immune system in health and disease","volume":"47","author":"Heutinck","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0115","doi-asserted-by":"crossref","first-page":"15072","DOI":"10.1073\/pnas.232422999","article-title":"Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma: possible relevance to human fibrotic disorders","volume":"99","author":"Frungieri","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.revmed.2020.06.006_bb0120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/17474086.2014.955008","article-title":"The serum tryptase test: an emerging robust biomarker in clinical hematology","volume":"7","author":"Valent","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jaci.2017.06.012","article-title":"Diagnosis and management of anaphylaxis in precision medicine","volume":"140","author":"Castells","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40413-015-0080-1","article-title":"2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines","volume":"8","author":"Simons","year":"2015","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.revmed.2020.06.006_bb0135","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0140","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000339749","article-title":"Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients","volume":"160","author":"Sala-Cunill","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0145","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonz\u00e1lez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.revmed.2020.06.006_bb0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.iac.2016.08.017","article-title":"Mastocytosis and Anaphylaxis","volume":"37","author":"Schuch","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.revmed.2020.06.006_bb0155","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/all.12272","article-title":"The epidemiology of anaphylaxis in Europe: a systematic review","volume":"68","author":"Panesar","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.revmed.2020.06.006_bb0160","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/ajh.24490","article-title":"Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study","volume":"91","author":"Broesby-Olsen","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0165","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11882-014-0450-8","article-title":"Anaphylaxis as a clinical manifestation of clonal mast cell disorders","volume":"14","author":"Matito","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.revmed.2020.06.006_bb0170","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/all.13380","article-title":"Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from the European anaphylaxis registry","volume":"73","author":"Worm","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.revmed.2020.06.006_bb0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2014.11.035","article-title":"Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels","volume":"136","author":"Zanotti","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0180","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","article-title":"Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis","volume":"27","author":"Rossini","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.revmed.2020.06.006_bb0185","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.iac.2018.04.010","article-title":"Hymenoptera anaphylaxis as a clonal mast cell disorder","volume":"38","author":"Bonadonna","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.revmed.2020.06.006_bb0190","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjh.16288","article-title":"The clinical and pathological panoply of systemic mastocytosis","volume":"188","author":"Radia","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.25371","article-title":"Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management","volume":"94","author":"Pardanani","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0200","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.iac.2018.04.005","article-title":"Kit mutations: new insights and diagnostic value","volume":"38","author":"Falchi","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.revmed.2020.06.006_bb0205","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.06.006_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20122976","article-title":"Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches","volume":"20","author":"Valent","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.revmed.2020.06.006_bb0215","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20%\u00a0+\u00a02 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0220","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jaip.2018.11.045","article-title":"Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.revmed.2020.06.006_bb0225","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.revmed.2020.06.006_bb0230","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"\u00c1lvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0235","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.revmed.2020.06.006_bb0240","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/10428190290021470","article-title":"Serum tryptase measurements in patients with myelodysplastic syndromes","volume":"43","author":"Sperr","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.revmed.2020.06.006_bb0245","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.06.006_bb0250","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000360164","article-title":"Serum tryptase: a new biomarker in patients with acute coronary syndrome?","volume":"164","author":"Pastorello","year":"2014","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000472","article-title":"Mast cells and acute coronary syndromes: relationship between serum tryptase, clinical outcome and severity of coronary artery disease","volume":"3","author":"Morici","year":"2016","journal-title":"Open Heart"},{"key":"10.1016\/j.revmed.2020.06.006_bb0260","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000500088","article-title":"Physiological roles of mast cells: collegium internationale allergologicum update 2019","volume":"179","author":"Varricchi","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0265","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fimmu.2018.00207","article-title":"Elevated systemic levels of eosinophil, neutrophil, and mast cell granular proteins in strongyloides stercoralis infection that diminish following treatment","volume":"9","author":"Rajamanickam","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0270","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1086\/344318","article-title":"Association of transient dermal mastocytosis and elevated plasma tryptase levels with development of adverse reactions after treatment of onchocerciasis with ivermectin","volume":"186","author":"Cooper","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.revmed.2020.06.006_bb0275","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cimid.2019.03.011","article-title":"Progenitor mast cells and tryptase in Q fever","volume":"64","author":"Mezouar","year":"2019","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.revmed.2020.06.006_bb0280","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2340\/00015555-1245","article-title":"Impact of age and heterophilic interference on the basal serum tryptase, a risk indication for anaphylaxis, in 1092 dermatology patients","volume":"92","author":"Schliemann","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0285","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/eci.12622","article-title":"Serum tryptase concentration and progression to end-stage renal disease","volume":"46","author":"Jesky","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.revmed.2020.06.006_bb0290","first-page":"282","article-title":"Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease","volume":"23","author":"Sirvent","year":"2010","journal-title":"J Nephrol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0295","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.21037\/tau.2018.11.03","article-title":"Biomarkers and the role of mast cells as facilitators of inflammation and fibrosis in chronic kidney disease","volume":"8","author":"Owens","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.revmed.2020.06.006_bb0300","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jaip.2017.08.039","article-title":"Persistent tryptase elevation in a patient with Gaucher disease","volume":"6","author":"Schussler","year":"2018","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320302046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320302046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:42:06Z","timestamp":1759336926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866320302046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0248866320302046"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2020.06.006","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosage de la tryptase\u00a0: un guide d'utilisation pour le clinicien","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2020.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}